Gravitate Health FHIR Implementation Guide (FHIR R4), published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health-ips/ and changes regularly. See the Directory of published versions
Example Bundle: Alicia Gravitate's IPS - Local
id:
Ovl-gravitate-Alicia
Composition status:
final
Composition Type:
Patient summary Document
Subject:
identifier:
alicia-1
Name:
Alicia Gravitate
active:
true
gender:
female
Birth Date:
1998-10-05
Sections
Problem List
Condition:
Depressive disorder (disorder) (35489007)
clinicalStatus:
active
Condition:
Human immunodeficiency virus infection (86406008)
clinicalStatus:
active
asserter:
Dr. Walter Waltz
onsetDateTime:
2018
Condition:
Trigeminal neuralgia (disorder) (31681005)
clinicalStatus:
active
asserter:
Dr. Walter Waltz
onsetDateTime:
2018
Condition:
Overweight (finding) (238131007)
clinicalStatus:
active
asserter:
Dr. Walter Waltz
onsetDateTime:
2018
Medication Summary
Medication:
BIKTARVY Bictegravir/Emtricitabine/Tenofovir Alafenamide 1 t QD
status:
active
Medication Detail:
-
System
https://spor.ema.europa.eu/pmswi
Code:
EU/1/18/1289/001 [Biktarvy 30 mg/120 mg/15 mg film-coated tablets]
-
System
https://www.who-umc.org/phpid
Code:
0x073AF2E5B92AE19E8B67635AFFB3D9nq [Biktarvy 30 mg/120 mg/15 mg film-coated tablets]
-
System
http://snomed.info/sct
Code:
774856007 [Product containing only bictegravir and emtricitabine and tenofovir (medicinal product)]
-
System
http://www.whocc.no/atc
Code:
J05AR20 [emtricitabine, tenofovir alafenamide and bictegravir]
Dose Form:
Coated tablet
Ingredient:
bictegravir (http://fdasis.nlm.nih.gov#8GB79LOJ07)
strength:
30 mg/1 Tablet
Ingredient:
emtricitabine (http://fdasis.nlm.nih.gov#G70B4ETF4S)
strength:
120 mg/1 Tablet
Ingredient:
tenofovir alafenamida (http://fdasis.nlm.nih.gov#EL9943AG5J)
strength:
15 mg/1 Tablet
Route:
Oral use
Medication:
CALCIO/VITAMINA D3 ROVI 1000 mg/880 UI COMPRIMIDOS EFERVESCENTES
status:
active
Route:
Oral use
Medication:
Carbamazepine 1 t TID
status:
active
Medication Detail:
-
System
https://spor.ema.europa.eu/pmswi
Code:
39.955 [Tegretol (Carbamazepine) 200 mg tablets]
-
System
https://www.who-umc.org/phpid
Code:
0x6e5dd079852edc5c3b8efce075c80a2e [Carbamazepine 200 mg tablets]
Dose Form:
Tablet
Ingredient:
CARBAMAZEPINE (http://fdasis.nlm.nih.gov#33CM23913M)
strength:
200 mg/1 Tablet
Route:
Oral use
Medication:
Orlistat 1 cp TID
status:
active
Medication Detail:
-
System
https://spor.ema.europa.eu/pmswi
Code:
EU/1/98/071/004 [Xenical (Orlistat) 60 mg capsule]
-
System
https://www.who-umc.org/phpid
Code:
0xc805ef896d1c2f5f17f84f34c909a9db [Xenical (Orlistat) 60 mg capsule]
Dose Form:
Capsule, hard
Ingredient:
ORLISTAT (http://fdasis.nlm.nih.gov#95M8R751W8)
strength:
60 mg/1 Tablet
Route:
Oral use
Medication:
St. John’s Wort 2 cp BID
status:
active
Route:
Oral use
Medication:
Flucelvax
status:
active
Route:
Intramuscular use
Medication:
Remsima 100 mg powder for concentrate for solution for infusion
status:
active
Route:
Intravenous use
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
